cg 806

BTK-IN-24 是一种布鲁顿酪氨酸激酶 （BTK）抑制剂，具有潜在的抗癌活性，可用于研究骨髓增生性疾病。

Luxeptinib (CG-806) is a novel pan-FLT3 pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4].